Literature DB >> 21857385

Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet.

Vassili Valayannopoulos1, Fanny Bajolle, Jean-Baptiste Arnoux, Sandrine Dubois, Nathalie Sannier, Christiane Baussan, François Petit, Philippe Labrune, Daniel Rabier, Chris Ottolenghi, Anne Vassault, Christine Broissand, Damien Bonnet, Pascale de Lonlay.   

Abstract

Glycogen storage disease type III (GSD III) due to debranching enzyme deficiency presenting usually with hepatomegaly and hypoglycemia may be responsible for severe cardiomyopathy which is often fatal. Current treatment of GSD III is based on frequent high-carbohydrate meals that have no effect on the cardiomyopathy. We describe a 2-mo-old infant presenting with a familial form of GSD III complicated with cardiomyopathy. As conventional treatment was unable to improve his sister's cardiomyopathy who was deceased at age 11 mo, we proposed an experimental treatment combining the use of synthetic ketone bodies (D,L-3-OH butyrate) as an alternative energy source, 2:1 ketogenic diet to reduce glucose intake and high-protein diet to enhance gluconeogenesis. Twenty-four months after the onset of this treatment, echocardiography showed an improvement of cardiomyopathy. Growth and liver size remained normal, and no side effects were observed. Blood glucose levels remained within the normal range and insulin levels decreased. These findings show that synthetic ketone bodies as well as low-carbohydrate, high-lipid, and high-protein diet may be a more beneficial therapeutic choice therapeutic choice for GSD III patients with cardiomyopathy. These encouraging data need to be confirmed in more GSD III patients presenting with cardiac or muscular symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21857385     DOI: 10.1203/PDR.0b013e318232154f

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  37 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Heart Failure Due to Severe Hypertrophic Cardiomyopathy Reversed by Low Calorie, High Protein Dietary Adjustments in a Glycogen Storage Disease Type IIIa Patient.

Authors:  Christiaan P Sentner; Kadir Caliskan; Wim B Vletter; G Peter A Smit
Journal:  JIMD Rep       Date:  2011-12-13

3.  Ketones and inborn errors of metabolism: old friends revisited.

Authors:  Rob C I Wüst; Gepke Visser; Ronald J A Wanders; Riekelt H Houtkooper
Journal:  J Inherit Metab Dis       Date:  2017-01       Impact factor: 4.982

4.  Dietary Management of the Glycogen Storage Diseases: Evolution of Treatment and Ongoing Controversies.

Authors:  Katalin M Ross; Iris A Ferrecchia; Kathryn R Dahlberg; Monika Dambska; Patrick T Ryan; David A Weinstein
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

Review 5.  Ketogenic diets in patients with inherited metabolic disorders.

Authors:  S Scholl-Bürgi; A Höller; K Pichler; M Michel; E Haberlandt; D Karall
Journal:  J Inherit Metab Dis       Date:  2015-06-25       Impact factor: 4.982

Review 6.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 7.  Infant with cardiomyopathy: When to suspect inborn errors of metabolism?

Authors:  Stephanie L Byers; Can Ficicioglu
Journal:  World J Cardiol       Date:  2014-11-26

8.  Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

Authors:  Patrice Vidal; Serena Pagliarani; Pasqualina Colella; Helena Costa Verdera; Louisa Jauze; Monika Gjorgjieva; Francesco Puzzo; Solenne Marmier; Fanny Collaud; Marcelo Simon Sola; Severine Charles; Sabrina Lucchiari; Laetitia van Wittenberghe; Alban Vignaud; Bernard Gjata; Isabelle Richard; Pascal Laforet; Edoardo Malfatti; Gilles Mithieux; Fabienne Rajas; Giacomo Pietro Comi; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Mol Ther       Date:  2017-12-28       Impact factor: 11.454

Review 9.  Dietary management in glycogen storage disease type III: what is the evidence?

Authors:  Terry G J Derks; G Peter A Smit
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

10.  Natural Progression of Canine Glycogen Storage Disease Type IIIa.

Authors:  Elizabeth D Brooks; Haiqing Yi; Stephanie L Austin; Beth L Thurberg; Sarah P Young; John C Fyfe; Priya S Kishnani; Baodong Sun
Journal:  Comp Med       Date:  2016-02       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.